4th Annual Stanford L. Kurland
Memorial Golf Classic
Benefiting brain cancer research for a cure
LOS ANGELES, CA
The urgent fight to end Glioblastoma
Glioblastoma (GBM) is a devastating, relentless disease. It is the most common and most fatal type of malignant brain tumor — there is no early detection or remission, and traditional therapies like radiation, chemotherapy and surgery are no match for its clutches.
Average survival is
only 8-12 months
40% survival in the
first year after
diagnosis, and only
20% in the second year
95% of brain cancers
come back either the
same or more
aggressively
The Stanford L. Kurland Memorial Golf Classic (SLK) has been on a mission since 2021 to fund vital research at UCLA Neuro-Oncology to champion a cure for GBM. This effort has already raised more than $7 million, making enormous strides and fueling hope. But we can’t stop now, with so much promise on the horizon for a possible cure.
The breakthroughs bringing new hope
Thanks to unwavering support and generosity from SLK sponsors and donors, UCLA has made groundbreaking discoveries and accelerated the drive toward a cure.
GBM cells mutate, making them extremely difficult to pinpoint and treat. UCLA researchers have now identified the transition point of cells, a critical discovery that opens the door to treatment that can attack tumor cells before they mutate.
SLK funding also has fueled the UCLA discovery that GBM has two blockers that repel treatment. KTM-101 effectively takes down one blocker, and now UCLA is assisting in the clinical development of a second drug to take down the second blocker. This one-two punch is an incredible advancement that ushers in a new era of fighting the disease.
Through SLK funding, UCLA developed the promising drug, KTM-101. Early clinical trial results show that the drug halted tumor growth for at least 6 months in over one-third of patients. The team is continuing this strong momentum to optimize this drug and explore combinations with other therapies.
Truly cutting-edge research is underway, with multiple Intellectual Property (IP) patents already filed. A major breakthrough includes the discovery of a novel drug that selectively targets a genetic mutation exclusive to GBM cells, resulting in significant tumor regression in preclinical models. This drug not only holds promise as a monotherapy but may also enhance immunotherapy efficacy. This drug candidate is projected to enter clinical trials within three years, marking a potential paradigm shift in GBM treatment.
The multipliers that make your
donations go further
Thanks to equipment in part funded by SLK, UCLA researchers can now obtain test results in a fraction of the time, enabling them to learn and iterate at lightning speed. Their groundbreaking one-stop research model makes it possible to create incredible efficiencies, for example bringing a drug to clinical trial for $3 million as opposed to the norm of $50-$100 million. This means your donated dollars go further, and your impact is even more profound.
The future brightened by a cure
The new therapies developed at UCLA, funded by SLK, are projected to be the standard of care within 4 years. Imagine the difference you can make. Together, we can end GBM and bring hope to patients and their families battling this brutal disease. We honor the legacy of Stan Kurland, and carry on the work he started before GBM took his life too soon.
Be part of the legacy. Make a lasting impact.